{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:35:41Z","timestamp":1791542141281,"version":"4.3.4"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.chest.2017.08.1159","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T14:01:40Z","timestamp":1504620100000},"page":"310-320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Ethnicity in Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"153","author":[{"given":"Sarah K.","family":"Medrek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25 suppl","key":"10.1016\/j.chest.2017.08.1159_bib1","doi-asserted-by":"crossref","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"Simonneau","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.chest.2017.08.1159_bib2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"Galie","year":"2015","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2017.08.1159_bib3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1164\/rccm.201311-1954ST","article-title":"An official American Thoracic Society statement: pulmonary hypertension phenotypes","volume":"189","author":"Dweik","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2017.08.1159_bib4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1086\/491747","article-title":"The use of racial, ethnic, and ancestral categories in human genetics research","volume":"77","year":"2005","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.chest.2017.08.1159_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ng0603-119","article-title":"MEDLINE definitions of race and ethnicity and their application to genetic research","volume":"34","author":"Sankar","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.chest.2017.08.1159_bib6","unstructured":"US Office of Management and Budget. Revisions to the standards for the classification of federal data on race and ethnicity. 1997. https:\/\/www.whitehouse.gov\/omb\/fedreg_1997standards. Accessed July 16, 2017."},{"key":"10.1016\/j.chest.2017.08.1159_bib7","unstructured":"National Institutes of Health. PHS inclusion enrollment report. 2016.https:\/\/grants.nih.gov\/grants\/forms\/phs-inclusion-enrollment-report.htm. Accessed August 22, 2017."},{"issue":"20","key":"10.1016\/j.chest.2017.08.1159_bib8","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1001\/jama.289.20.2709","article-title":"Use of race and ethnicity in biomedical publication","volume":"289","author":"Kaplan","year":"2003","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.chest.2017.08.1159_bib9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.chest.2017.08.1159_bib10","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2017.08.1159_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10741-015-9510-y","article-title":"Definition, epidemiology and registries of pulmonary hypertension","volume":"21","author":"Awdish","year":"2016","journal-title":"Heart Fail Rev"},{"issue":"25 suppl","key":"10.1016\/j.chest.2017.08.1159_bib12","doi-asserted-by":"crossref","first-page":"D51","DOI":"10.1016\/j.jacc.2013.10.023","article-title":"Pulmonary arterial hypertension: epidemiology and registries","volume":"62","author":"McGoon","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.chest.2017.08.1159_bib13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.chest.2017.08.1159_bib14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ahj.2006.02.020","article-title":"Temporal trends and drug exposures in pulmonary hypertension: an American experience","volume":"152","author":"Walker","year":"2006","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.chest.2017.08.1159_bib15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1378\/chest.10-0075","article-title":"The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries","volume":"139","author":"Frost","year":"2011","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.chest.2017.08.1159_bib16","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1164\/rccm.201203-0383OC","article-title":"Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland","volume":"186","author":"Ling","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2017.08.1159_bib17","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1378\/chest.117.3.796","article-title":"Mortality from primary pulmonary hypertension in the United States, 1979-1996","volume":"117","author":"Lilienfeld","year":"2000","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2017.08.1159_bib18","first-page":"1","article-title":"Pulmonary hypertension surveillance\u2014United States, 1980-2002","volume":"54","author":"Hyduk","year":"2005","journal-title":"MMWR Surveill Summ"},{"issue":"2","key":"10.1016\/j.chest.2017.08.1159_bib19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1378\/chest.14-0527","article-title":"Pulmonary hypertension surveillance: United States, 2001 to 2010","volume":"146","author":"George","year":"2014","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2017.08.1159_bib20","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1378\/chest.15-0300","article-title":"Five-year outcomes of patients enrolled in the REVEAL Registry","volume":"148","author":"Farber","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.chest.2017.08.1159_bib21","first-page":"A7473","article-title":"Racial and ethnic differences in pulmonary arterial hypertension","volume":"195","author":"Al-Naamani","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2017.08.1159_bib22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.amjcard.2004.09.006","article-title":"New predictors of outcome in idiopathic pulmonary arterial hypertension","volume":"95","author":"Kawut","year":"2005","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.chest.2017.08.1159_bib23","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.amjcard.2005.05.001","article-title":"Race as an independent prognostic factor in patients with idiopathic pulmonary arterial hypertension","volume":"96","author":"Minai","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.chest.2017.08.1159_bib24","first-page":"A4232","article-title":"Minority patients with pulmonary arterial hypertension present with more severe disease at the time of diagnosis","volume":"195","author":"Usmani","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2017.08.1159_bib25","first-page":"A4255","article-title":"Characterization of hispanics with pulmonary hypertension in the US: the Pulmonary Hypertension Association Registry","volume":"295","author":"De Jesus Perez","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2017.08.1159_bib26","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1378\/chest.14-2919","article-title":"Idiopathic pulmonary arterial hypertension in Asians: a long-term study on clinical outcomes","volume":"147","author":"Tan","year":"2015","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2017.08.1159_bib27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1378\/chest.06-2913","article-title":"Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension","volume":"132","author":"Jing","year":"2007","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2017.08.1159_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","article-title":"Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era","volume":"179","author":"Condliffe","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2017.08.1159_bib29","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1183\/09031936.00182813","article-title":"Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients","volume":"44","author":"Hao","year":"2014","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.chest.2017.08.1159_bib30","first-page":"1277","article-title":"Ethnic disparities among patients with pulmonary hypertension associated with systemic sclerosis","volume":"34","author":"Beall","year":"2007","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.chest.2017.08.1159_bib31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/MD.0000000000000032","article-title":"Severity of systemic sclerosis-associated pulmonary arterial hypertension in African Americans","volume":"93","author":"Blanco","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.chest.2017.08.1159_bib32","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1378\/chest.11-0160","article-title":"Portopulmonary hypertension: a report from the US-based REVEAL Registry","volume":"141","author":"Krowka","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2017.08.1159_bib33","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/path.4833","article-title":"The role of genetics in pulmonary arterial hypertension","volume":"241","author":"Ma","year":"2017","journal-title":"J\u00a0Pathol"},{"issue":"1","key":"10.1016\/j.chest.2017.08.1159_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1164\/rccm.201605-0905PP","article-title":"Translational advances in the field of pulmonary hypertension molecular medicine of pulmonary arterial hypertension. From population genetics to precision medicine and gene editing","volume":"195","author":"Austin","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.chest.2017.08.1159_bib35","doi-asserted-by":"crossref","first-page":"e15269","DOI":"10.1371\/journal.pone.0015269","article-title":"Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications","volume":"5","author":"Volkow","year":"2010","journal-title":"PLoS One"},{"issue":"231","key":"10.1016\/j.chest.2017.08.1159_bib36","first-page":"1","article-title":"Recent trends in heart failure-related mortality: United States, 2000-2014","author":"Ni","year":"2015","journal-title":"NCHS Data Brief"},{"issue":"19","key":"10.1016\/j.chest.2017.08.1159_bib37","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.168.19.2138","article-title":"Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis","volume":"168","author":"Bahrami","year":"2008","journal-title":"Arch Intern Med"},{"issue":"6 suppl 2","key":"10.1016\/j.chest.2017.08.1159_bib38","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.2214\/AJR.04.1868","article-title":"Cardiovascular function in multi-ethnic study of atherosclerosis: normal values by age, sex, and ethnicity","volume":"186","author":"Natori","year":"2006","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.chest.2017.08.1159_bib39","doi-asserted-by":"crossref","first-page":"e001264","DOI":"10.1161\/JAHA.114.001264","article-title":"Race-ethnic and sex differences in left ventricular structure and function: the Coronary Artery Risk Development in Young Adults (CARDIA) study","volume":"4","author":"Kishi","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"21","key":"10.1016\/j.chest.2017.08.1159_bib40","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1161\/01.CIR.0000129087.81352.7A","article-title":"Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases","volume":"109","author":"Kalinowski","year":"2004","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.chest.2017.08.1159_bib41","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.107.704023","article-title":"Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics","volume":"118","author":"Johnson","year":"2008","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.chest.2017.08.1159_bib42","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jacc.2006.07.030","article-title":"Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial","volume":"48","author":"McNamara","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.chest.2017.08.1159_bib43","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jchf.2014.06.010","article-title":"Race, common genetic variation, and therapeutic response disparities in heart failure","volume":"2","author":"Taylor","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"6 suppl","key":"10.1016\/j.chest.2017.08.1159_bib44","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1378\/chest.09-2445","article-title":"High-altitude disorders: pulmonary hypertension: pulmonary vascular disease: the global perspective","volume":"137","author":"Pasha","year":"2010","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2017.08.1159_bib45","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1086\/688315","article-title":"Pulmonary vascular and ventricular dysfunction in the susceptible patient (2015 Grover Conference series)","volume":"6","author":"Maron","year":"2016","journal-title":"Pulm Circ"},{"issue":"3","key":"10.1016\/j.chest.2017.08.1159_bib46","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1164\/rccm.201604-0882PP","article-title":"Focusing on developmental origins and disease inception for the prevention of pulmonary hypertension","volume":"195","author":"Maron","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"169","key":"10.1016\/j.chest.2017.08.1159_bib47","first-page":"1","article-title":"Trends in fetal and perinatal mortality in the United States, 2006-2012","author":"Gregory","year":"2014","journal-title":"NCHS Data Brief"},{"issue":"5","key":"10.1016\/j.chest.2017.08.1159_bib48","doi-asserted-by":"crossref","first-page":"e0156042","DOI":"10.1371\/journal.pone.0156042","article-title":"Mitochondrial haplogroups and risk of pulmonary arterial hypertension","volume":"11","author":"Farha","year":"2016","journal-title":"PLoS One"},{"issue":"22","key":"10.1016\/j.chest.2017.08.1159_bib49","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1161\/CIRCULATIONAHA.110.985515","article-title":"Sex and race differences in right ventricular structure and function: the multi-ethnic study of atherosclerosis-right ventricle study","volume":"123","author":"Kawut","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.chest.2017.08.1159_bib50","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1183\/13993003.01083-2015","article-title":"Oestradiol metabolism and androgen receptor genotypes are associated with right ventricular function","volume":"47","author":"Ventetuolo","year":"2016","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2017.08.1159_bib51","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1152\/japplphysiol.00466.2015","article-title":"Pulmonary vascular function and exercise capacity in black sub-Saharan Africans","volume":"119","author":"Simaga","year":"2015","journal-title":"J\u00a0Appl Physiol (1985)"},{"issue":"4","key":"10.1016\/j.chest.2017.08.1159_bib52","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0002-9149(96)00344-X","article-title":"Racial and gender differences in endothelin-1","volume":"78","author":"Evans","year":"1996","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.chest.2017.08.1159_bib53","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/01.HYP.35.3.722","article-title":"Racial differences in endothelin-1 at rest and in response to acute stress in adolescent males","volume":"35","author":"Treiber","year":"2000","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.chest.2017.08.1159_bib54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1378\/chest.11-0404","article-title":"Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension","volume":"141","author":"Gabler","year":"2012","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.chest.2017.08.1159_bib55","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1164\/rccm.201501-0196OC","article-title":"Endothelin-1 pathway polymorphisms and outcomes in pulmonary arterial hypertension","volume":"192","author":"Benza","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"21","key":"10.1016\/j.chest.2017.08.1159_bib56","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1161\/CIRCULATIONAHA.110.012781","article-title":"Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions","volume":"123","author":"Cole","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.chest.2017.08.1159_bib57","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.amjcard.2014.04.018","article-title":"Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial","volume":"114","author":"Ferdinand","year":"2014","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.chest.2017.08.1159_bib58","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/sj.clpt.6100482","article-title":"Pharmacokinetics\/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations","volume":"84","author":"Myrand","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"23","key":"10.1016\/j.chest.2017.08.1159_bib59","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1161\/CIRCULATIONAHA.114.006980","article-title":"Emerging concepts in the molecular basis of pulmonary arterial hypertension: part ii: neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension","volume":"131","author":"Maron","year":"2015","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.chest.2017.08.1159_bib60","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jama.297.10.1118","article-title":"Health disparities and access to health","volume":"297","author":"Lurie","year":"2007","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.chest.2017.08.1159_bib61","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1164\/rccm.201207-1290OC","article-title":"Lower socioeconomic status is associated with worse outcomes in pulmonary arterial hypertension","volume":"187","author":"Wu","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2017.08.1159_bib62","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1086\/686489","article-title":"Socioeconomic status affects pulmonary hypertension disease severity at time of first evaluation","volume":"6","author":"Talwar","year":"2016","journal-title":"Pulm Circ"},{"issue":"2","key":"10.1016\/j.chest.2017.08.1159_bib63","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.chest.2017.08.1159_bib64","first-page":"A6907","article-title":"Socioeconomic factors are associated with health-related quality of life in patients with pulmonary hypertension","volume":"195","author":"Al-Naamani","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2017.08.1159_bib65","doi-asserted-by":"crossref","first-page":"314","DOI":"10.7326\/0003-4819-150-5-200903030-00007","article-title":"Factors associated with racial differences in myocardial infarction outcomes","volume":"150","author":"Spertus","year":"2009","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.chest.2017.08.1159_bib66","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.chest.2017.08.1159_bib67","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A\u00a0comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.chest.2017.08.1159_bib68","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.chest.2017.08.1159_bib69","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.chest.2017.08.1159_bib70","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.chest.2017.08.1159_bib71","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial","volume":"142","author":"Tapson","year":"2012","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2017.08.1159_bib72","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1378\/chest.12-2875","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial","volume":"144","author":"Tapson","year":"2013","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2017.08.1159_bib73","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"9288","key":"10.1016\/j.chest.2017.08.1159_bib74","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.chest.2017.08.1159_bib75","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.chest.2017.08.1159_bib76","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.chest.2017.08.1159_bib77","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.chest.2017.08.1159_bib78","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.chest.2017.08.1159_bib79","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Galie","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.chest.2017.08.1159_bib80","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","article-title":"Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial","volume":"127","author":"Jing","year":"2013","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.chest.2017.08.1159_bib81","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.chest.2017.08.1159_bib82","first-page":"2268","article-title":"Authors of CHEST-1 and PATENT-1. Riociguat for pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.chest.2017.08.1159_bib83","first-page":"630","article-title":"Why African Americans may not be participating in clinical trials","volume":"88","author":"Harris","year":"1996","journal-title":"J\u00a0Natl Med Assoc"},{"issue":"1","key":"10.1016\/j.chest.2017.08.1159_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0b013e3181625d78","article-title":"Race, medical researcher distrust, perceived harm, and willingness to participate in cardiovascular prevention trials","volume":"87","author":"Braunstein","year":"2008","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.chest.2017.08.1159_bib85","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.23157","article-title":"Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review","volume":"112","author":"Ford","year":"2008","journal-title":"Cancer"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369217326776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369217326776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:02:16Z","timestamp":1757923336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369217326776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0012369217326776"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2017.08.1159","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ethnicity in Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2017.08.1159","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}